Seelos falls on failed ALS drug study

Seelos Therapeutics

19/03/2024 13:49

** Shares of Seelos Therapeutics  SEEL.O  down 51% at 45
cents
    ** Co's experimental drug for amyotrophic lateral sclerosis
(ALS), a neurological disorder, failed to meet the main goal in
a mid-stage trial
    ** Drug SLS-005 did not show any statistical significance in
improving function and mortality during the trial
    ** ALS is a disease that affects nerve cells in the brain
and spinal cord that are responsible for muscle movements,
eventually leading to paralysis and death
    ** Stock down 33.9% YTD

 (Reporting by Sruthi Narasimha Chari in Bengaluru)
 ((Sruthinarasimha.chari@thomsonreuters.com))